Literature DB >> 25534387

Receipt of chemotherapy among medicare patients with cancer by type of supplemental insurance.

Joan L Warren1, Eboneé N Butler2, Jennifer Stevens2, Christopher S Lathan2, Anne-Michelle Noone2, Kevin C Ward2, Linda C Harlan2.   

Abstract

PURPOSE: Medicare beneficiaries with cancer bear a greater portion of their health care costs, because cancer treatment costs have increased. Beneficiaries have supplemental insurance to reduce out-of-pocket costs; those without supplemental insurance may face barriers to care. This study examines the association between type of supplemental insurance coverage and receipt of chemotherapy among Medicare patients with cancer who, per National Comprehensive Cancer Network treatment guidelines, should generally receive chemotherapy. PATIENTS AND METHODS: This retrospective, observational study included 1,200 Medicare patients diagnosed with incident cancer of the breast (stage IIB to III), colon (stage III), rectum (stage II to III), lung (stage II to IV), or ovary (stage II to IV) from 2000 to 2005. Using the National Cancer Institute Patterns of Care Studies and linked SEER-Medicare data, we determined each Medicare patient's supplemental insurance status (private insurance, dual eligible [ie, Medicare with Medicaid], or no supplemental insurance), consultation with an oncologist, and receipt of chemotherapy. Using adjusted logistic regression, we evaluated the association of type of supplemental insurance with oncologist consultation and receipt of chemotherapy.
RESULTS: Dual-eligible patients were significantly less likely to receive chemotherapy than were Medicare patients with private insurance. Patients with Medicare only who saw an oncologist had comparable rates of chemotherapy compared with Medicare patients with private insurance.
CONCLUSION: Dual-eligible Medicare beneficiaries received recommended cancer chemotherapy less frequently than other Medicare beneficiaries. With the increasing number of Medicaid patients under the Affordable Care Act, there will be a need for patient navigators and sufficient physician reimbursement so that low-income patients with cancer will have access to oncologists and needed treatment.
© 2014 by American Society of Clinical Oncology.

Entities:  

Mesh:

Year:  2014        PMID: 25534387      PMCID: PMC4302213          DOI: 10.1200/JCO.2014.55.3107

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  16 in total

1.  Predictive margins with survey data.

Authors:  B I Graubard; E L Korn
Journal:  Biometrics       Date:  1999-06       Impact factor: 2.571

2.  Overview of the SEER-Medicare data: content, research applications, and generalizability to the United States elderly population.

Authors:  Joan L Warren; Carrie N Klabunde; Deborah Schrag; Peter B Bach; Gerald F Riley
Journal:  Med Care       Date:  2002-08       Impact factor: 2.983

3.  Trends in out-of-pocket healthcare costs among older community-dwelling Medicare beneficiaries.

Authors:  Gerald F Riley
Journal:  Am J Manag Care       Date:  2008-10       Impact factor: 2.229

4.  Insurance status and the use of guideline therapy in the treatment of selected cancers.

Authors:  Linda C Harlan; Amanda L Greene; Limin X Clegg; Margaret Mooney; Jennifer L Stevens; Martin L Brown
Journal:  J Clin Oncol       Date:  2005-11-21       Impact factor: 44.544

5.  Future supply and demand for oncologists : challenges to assuring access to oncology services.

Authors:  Clese Erikson; Edward Salsberg; Gaetano Forte; Suanna Bruinooge; Michael Goldstein
Journal:  J Oncol Pract       Date:  2007-03       Impact factor: 3.840

6.  Inadequate access to surgeons: reason for disparate cancer care?

Authors:  Cathy J Bradley; Bassam Dahman; Charles W Given
Journal:  Med Care       Date:  2009-07       Impact factor: 2.983

7.  The utility of the state buy-in variable in the Medicare denominator file to identify dually eligible Medicare-Medicaid beneficiaries: a validation study.

Authors:  Siran M Koroukian; Bassam Dahman; Glenn Copeland; Cathy J Bradley
Journal:  Health Serv Res       Date:  2009-10-15       Impact factor: 3.402

8.  Evaluation of trends in the cost of initial cancer treatment.

Authors:  Joan L Warren; K Robin Yabroff; Angela Meekins; Marie Topor; Elizabeth B Lamont; Martin L Brown
Journal:  J Natl Cancer Inst       Date:  2008-06-10       Impact factor: 13.506

9.  Who does not receive treatment for cancer?

Authors:  Marcia M Ward; Fred Ullrich; Kevin Matthews; Gerard Rushton; Michael A Goldstein; Dean F Bajorin; Amy Hanley; Charles F Lynch
Journal:  J Oncol Pract       Date:  2013-01       Impact factor: 3.840

10.  Patient out-of-pocket payments for oral oncolytics: results from a 2009 US claims data analysis.

Authors:  Martin L Raborn; Elise M Pelletier; Daniel B Smith; Carolina M Reyes
Journal:  Am J Manag Care       Date:  2012-05       Impact factor: 2.229

View more
  17 in total

1.  Care experiences among dually enrolled older adults with cancer: SEER-CAHPS, 2005-2013.

Authors:  Lisa M Lines; Julia Cohen; Michael T Halpern; Ashley Wilder Smith; Erin E Kent
Journal:  Cancer Causes Control       Date:  2019-08-17       Impact factor: 2.506

2.  Adherence to treatment guidelines and survival for older patients with stage II or III colon cancer in Texas from 2001 through 2011.

Authors:  Hui Zhao; Ning Zhang; Vivian Ho; Minming Ding; Weiguo He; Jiangong Niu; Ming Yang; Xianglin L Du; Daria Zorzi; Mariana Chavez-MacGregor; Sharon H Giordano
Journal:  Cancer       Date:  2017-11-15       Impact factor: 6.860

3.  Survival Gains from First-Line Systemic Therapy in Metastatic Non-Small Cell Lung Cancer in the U.S., 1990-2015: Progress and Opportunities.

Authors:  Joshua A Roth; Bernardo H L Goulart; Arliene Ravelo; Holli Kolkey; Scott D Ramsey
Journal:  Oncologist       Date:  2017-02-27

4.  First-line treatment in older patients with Hodgkin lymphoma: a Surveillance, Epidemiology, and End Results (SEER)-Medicare population-based study.

Authors:  Angie Mae Rodday; Theresa Hahn; Anita J Kumar; Peter K Lindenauer; Jonathan W Friedberg; Andrew M Evens; Susan K Parsons
Journal:  Br J Haematol       Date:  2020-02-23       Impact factor: 6.998

5.  Underutilization of gene expression profiling for early-stage breast cancer in California.

Authors:  Rosemary D Cress; Yingjia S Chen; Cyllene R Morris; Helen Chew; Kenneth W Kizer
Journal:  Cancer Causes Control       Date:  2016-04-20       Impact factor: 2.506

6.  Annual Medical Expenditure and Productivity Loss Among Colorectal, Female Breast, and Prostate Cancer Survivors in the United States.

Authors:  Zhiyuan Zheng; K Robin Yabroff; Gery P Guy; Xuesong Han; Chunyu Li; Matthew P Banegas; Donatus U Ekwueme; Ahmedin Jemal
Journal:  J Natl Cancer Inst       Date:  2015-12-24       Impact factor: 13.506

7.  Chemotherapy Use, End-of-Life Care, and Costs of Care Among Patients Diagnosed With Stage IV Pancreatic Cancer.

Authors:  Yuhua Bao; Renee C Maciejewski; Melissa M Garrido; Manish A Shah; Paul K Maciejewski; Holly G Prigerson
Journal:  J Pain Symptom Manage       Date:  2017-12-11       Impact factor: 3.612

8.  Effects of Transitioning to Medicare Part D on Access to Drugs for Medical Conditions among Dual Enrollees with Cancer.

Authors:  Alyce S Adams; Jeanne M Madden; Fang Zhang; Christine Y Lu; Dennis Ross-Degnan; Angelina Lee; Stephen B Soumerai; Dan Gilden; Neetu Chawla; Jennifer J Griggs
Journal:  Value Health       Date:  2017-07-06       Impact factor: 5.725

9.  A review of cancer outcomes among persons dually enrolled in Medicare and Medicaid.

Authors:  Steven S Coughlin; Lee Caplan; Lufei Young
Journal:  J Hosp Manag Health Policy       Date:  2018-07-20

10.  Metastatic Melanoma: Treatment and Survival in the US after the Introduction of Ipilimumab and Vemurafenib.

Authors:  Lindsey Enewold; Elad Sharon; Linda C Harlan
Journal:  Oncol Res Treat       Date:  2017-03-09       Impact factor: 2.844

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.